| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9ac3d1a365829a0effbf0e16e7b1b8e2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate |
2019-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a269763c59bbe961048865a69c2a5d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_842ee746a62e46af360536831a3068f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34822d276ef857ec5dc9802b40be0e2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f69e3c51f3c4be970f5180080430a935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd45d1634bcb025ae8a7fcf44bd3d326
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbf143d44c7e606b2aa5b9bd70d60fa3 |
| publicationDate |
2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2022000971-A1 |
| titleOfInvention |
Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry |
| abstract |
The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X 1 X 2 X 3 X 4 X 5 GVX 6 AKAGVX 7 NX 8 FKSESY (I) (SEQ ID NO: 1) (X 9 ) n GVX 10 AKAGVX 11 NX 12 FKSESY (II) (SEQ ID NO: 2) YKX 13 LRRX 14 APRWDX 15 PLRDPALRX 16 X 17 L (III) (SEQ ID NO: 3) YKX 18 LRR(X 19 ) n PLRDPALRX 20 X 21 L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X 1 to X 21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end, for use in inhibiting vasculogenic mimicry and/or for treating a cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11780882-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022356209-A1 |
| priorityDate |
2018-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |